Seneca House Advisors Has $632,000 Holdings in Thermo Fisher Scientific Inc. $TMO

Seneca House Advisors lessened its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 88.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,091 shares of the medical research company’s stock after selling 8,096 shares during the period. Seneca House Advisors’ holdings in Thermo Fisher Scientific were worth $632,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in TMO. Assetmark Inc. increased its stake in Thermo Fisher Scientific by 22.9% in the 4th quarter. Assetmark Inc. now owns 37,654 shares of the medical research company’s stock valued at $21,819,000 after buying an additional 7,023 shares during the last quarter. Mackenzie Financial Corp increased its stake in Thermo Fisher Scientific by 29.4% in the 3rd quarter. Mackenzie Financial Corp now owns 276,545 shares of the medical research company’s stock valued at $134,130,000 after buying an additional 62,790 shares during the last quarter. NEOS Investment Management LLC increased its stake in Thermo Fisher Scientific by 28.6% in the 3rd quarter. NEOS Investment Management LLC now owns 51,364 shares of the medical research company’s stock valued at $24,913,000 after buying an additional 11,415 shares during the last quarter. Factory Mutual Insurance Co. increased its stake in Thermo Fisher Scientific by 2.6% in the 3rd quarter. Factory Mutual Insurance Co. now owns 98,935 shares of the medical research company’s stock valued at $47,985,000 after buying an additional 2,500 shares during the last quarter. Finally, North Dakota State Investment Board purchased a new stake in Thermo Fisher Scientific in the 4th quarter valued at about $7,505,000. Institutional investors and hedge funds own 89.23% of the company’s stock.

Thermo Fisher Scientific Stock Down 0.2%

TMO opened at $472.73 on Wednesday. The company has a 50 day moving average of $478.34 and a 200 day moving average of $525.54. The company has a market cap of $175.68 billion, a PE ratio of 25.99, a price-to-earnings-growth ratio of 2.10 and a beta of 0.88. Thermo Fisher Scientific Inc. has a 12 month low of $385.46 and a 12 month high of $643.99. The company has a current ratio of 1.53, a quick ratio of 1.15 and a debt-to-equity ratio of 0.77.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Thursday, April 23rd. The medical research company reported $5.44 EPS for the quarter, topping the consensus estimate of $5.25 by $0.19. The company had revenue of $11.01 billion during the quarter, compared to the consensus estimate of $10.86 billion. Thermo Fisher Scientific had a net margin of 15.15% and a return on equity of 16.86%. Thermo Fisher Scientific’s revenue for the quarter was up 6.2% on a year-over-year basis. During the same period last year, the firm earned $5.15 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. On average, sell-side analysts expect that Thermo Fisher Scientific Inc. will post 24.85 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, July 15th. Shareholders of record on Monday, June 15th will be issued a $0.47 dividend. This represents a $1.88 annualized dividend and a yield of 0.4%. The ex-dividend date of this dividend is Monday, June 15th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.34%.

Insider Buying and Selling

In other Thermo Fisher Scientific news, COO Gianluca Pettiti sold 400 shares of the firm’s stock in a transaction on Monday, April 27th. The shares were sold at an average price of $462.66, for a total value of $185,064.00. Following the completion of the transaction, the chief operating officer directly owned 25,051 shares of the company’s stock, valued at $11,590,095.66. This trade represents a 1.57% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.33% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

TMO has been the subject of a number of research reports. Morgan Stanley reissued an “overweight” rating and set a $620.00 target price on shares of Thermo Fisher Scientific in a research report on Monday, April 27th. Barclays reduced their target price on shares of Thermo Fisher Scientific from $650.00 to $625.00 and set an “overweight” rating for the company in a research report on Tuesday, April 14th. Wolfe Research initiated coverage on shares of Thermo Fisher Scientific in a research report on Tuesday, June 2nd. They set an “outperform” rating and a $535.00 target price for the company. Piper Sandler initiated coverage on shares of Thermo Fisher Scientific in a research report on Thursday, June 11th. They set a “neutral” rating and a $510.00 target price for the company. Finally, Robert W. Baird reduced their target price on shares of Thermo Fisher Scientific from $653.00 to $639.00 and set an “outperform” rating for the company in a research report on Friday, April 24th. Two analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and five have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $608.95.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.